Abamectin
CAS No. 71751-41-2
Abamectin ( Abamectin, Affirm, Avid, Avid EC, Avomec, EPA Pesticide Chemical Code 122804, HSDB 6941, MK 0936 )
产品货号. M15742 CAS No. 71751-41-2
Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic.
纯度: >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
50MG | ¥308 | 有现货 |
|
100MG | ¥405 | 有现货 |
|
200MG | ¥446 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Abamectin
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic.
-
产品描述Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic.
-
同义词Abamectin, Affirm, Avid, Avid EC, Avomec, EPA Pesticide Chemical Code 122804, HSDB 6941, MK 0936
-
通路Others
-
靶点Other Targets
-
受体Antiparasitic
-
研究领域Infection
-
适应症——
化学信息
-
CAS Number71751-41-2
-
分子量873.09
-
分子式C48H72O14
-
纯度>98%(HPLC)
-
溶解度DMSO: 10 mM
-
SMILESC[C@H]1[C@H](O)[C@@H](OC)C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]([C@@H](C)/C=C/C=C3CO[C@@]4([H])[C@]\3(O)[C@@]5([H])C=C(C)[C@H]4O)/C(C)=C/C[C@]6([H])C[C@H](OC5=O)C[C@@]7(O[C@H](C(C)C)[C@@H](C)C=C7)O6)C[C@@H]2OC)O1.C[C@H]8[C@H](O)[C@@H](OC)C[C@H](O[C@H]9[C@H](C)O[C@@H](O[C@@H]([C@@H](C)/C=C/C=C%10CO[C@@]%11([H])[C@]\%10(O)[C@@]%12([H])C=C(C)[C@H]%11O)/C(C)=C/C[C@]%13([H])C[C@H](OC%12=O)C[C@@]%14(O[C@H]([C@@H](CC)C)[C@@H](C)C=C%14)O%13)C[C@@H]9OC)O8
-
化学全称Avermectin B(sub 1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Mogg TD, et al. Aust Vet J. 1990 Nov;67(11):399-40
产品手册
关联产品
-
(+)-beta-Cedrene
β-cedrene are bioactive sesquiterpenes found in cedar essential oil and exert antiseptic, anti-inflammatory, antispasmodic, tonic, astringent, diuretic, sedative, insecticidal, and antifungal activities.
-
Methyl nomilinate
Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.
-
MAGE-A3 195-203
This peptide MAGE-3-encoded HLA-A24 epitope is a high MHC binder.The identification of this MAGE-3/HLA-A24 peptide may as a result effectiveially offer the opportunities to design peptide-based immunotherapeutic approaches that might prove to be potent in treating patients with MAGE-3-positive malignant tumors.